136 related articles for article (PubMed ID: 17551301)
1. Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese.
Okuno T; Tamura T; Yamamori M; Chayahara N; Yamada T; Miki I; Okamura N; Kadowaki Y; Shirasaka D; Aoyama N; Nakamura T; Okumura K; Azuma T; Kasuga M; Sakaeda T
Am J Clin Oncol; 2007 Jun; 30(3):252-7. PubMed ID: 17551301
[TBL] [Abstract][Full Text] [Related]
2. Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Kuwahara A; Yamamori M; Kadoyama K; Nishiguchi K; Nakamura T; Miki I; Tamura T; Okuno T; Omatsu H; Sakaeda T
J Exp Clin Cancer Res; 2011 Oct; 30(1):94. PubMed ID: 21970688
[TBL] [Abstract][Full Text] [Related]
3. TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Kuwahara A; Yamamori M; Fujita M; Okuno T; Tamura T; Kadoyama K; Okamura N; Nakamura T; Sakaeda T
J Exp Clin Cancer Res; 2010 Jul; 29(1):100. PubMed ID: 20646319
[TBL] [Abstract][Full Text] [Related]
4. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients.
Sakaeda T; Yamamori M; Kuwahara A; Hiroe S; Nakamura T; Okumura K; Okuno T; Miki I; Chayahara N; Okamura N; Tamura T
Ther Drug Monit; 2008 Aug; 30(4):497-503. PubMed ID: 18641541
[TBL] [Abstract][Full Text] [Related]
5. VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Tamura T; Kuwahara A; Yamamori M; Nishiguchi K; Nakamura T; Okuno T; Miki I; Manabe Y; Sakaeda T
Int J Med Sci; 2012; 9(10):833-7. PubMed ID: 23155356
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
Kato K; Muro K; Minashi K; Ohtsu A; Ishikura S; Boku N; Takiuchi H; Komatsu Y; Miyata Y; Fukuda H;
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):684-90. PubMed ID: 20932658
[TBL] [Abstract][Full Text] [Related]
7. Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma.
Kuwahara A; Yamamori M; Nishiguchi K; Okuno T; Chayahara N; Miki I; Tamura T; Kadoyama K; Inokuma T; Takemoto Y; Nakamura T; Kataoka K; Sakaeda T
Int J Med Sci; 2010 Jan; 7(1):48-54. PubMed ID: 20151048
[TBL] [Abstract][Full Text] [Related]
8. TNF-α -857C>T genotype is predictive of clinical response after treatment with definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Omatsu H; Kuwahara A; Yamamori M; Fujita M; Okuno T; Miki I; Tamura T; Nishiguchi K; Okamura N; Nakamura T; Azuma T; Hirano T; Ozawa K; Hirai M
Int J Med Sci; 2013; 10(12):1755-60. PubMed ID: 24151445
[TBL] [Abstract][Full Text] [Related]
9. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
[TBL] [Abstract][Full Text] [Related]
10. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
Hashimoto J; Kato K; Ito Y; Kojima T; Akimoto T; Daiko H; Hamamoto Y; Matsushita H; Katano S; Hara H; Tanaka Y; Saito Y; Nagashima K; Igaki H
Int J Clin Oncol; 2019 Jan; 24(1):60-67. PubMed ID: 30109544
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Minegaki T; Kuwahara A; Yamamori M; Nakamura T; Okuno T; Miki I; Omatsu H; Tamura T; Hirai M; Azuma T; Sakaeda T; Nishiguchi K
Int J Med Sci; 2014; 11(4):321-6. PubMed ID: 24578608
[TBL] [Abstract][Full Text] [Related]
12. Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Kuwahara A; Yamamori M; Nishiguchi K; Okuno T; Chayahara N; Miki I; Tamura T; Inokuma T; Takemoto Y; Nakamura T; Kataoka K; Sakaeda T
Int J Med Sci; 2009 Sep; 6(6):305-11. PubMed ID: 19834547
[TBL] [Abstract][Full Text] [Related]
13. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma.
Lee JL; Park SI; Kim SB; Jung HY; Lee GH; Kim JH; Song HY; Cho KJ; Kim WK; Lee JS; Kim SH; Min YI
Ann Oncol; 2004 Jun; 15(6):947-54. PubMed ID: 15151953
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of escalating-dose cisplatin with 5-fluorouracil and concurrent radiotherapy in Chinese patients with esophageal cancer.
Lin Q; Gao XS; Qiao XY; Zhou ZG; Zhang P; Chen K; Zhao YN; Asaumi J
Acta Med Okayama; 2008 Feb; 62(1):37-44. PubMed ID: 18323870
[TBL] [Abstract][Full Text] [Related]
15. TS gene tandem repeats in esophageal cancer patients receiving chemoradiotherapy.
Kaneko K; Nagai M; Murakami Y; Kogo M; Oyama T; Kojima T; Ohtsu A; Imawari M
Front Biosci (Landmark Ed); 2011 Jan; 16(3):1036-43. PubMed ID: 21196216
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166
[TBL] [Abstract][Full Text] [Related]
17. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
Weiner LM; Colarusso P; Goldberg M; Dresler C; Coia LR
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-93-S19-95. PubMed ID: 9427276
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
[TBL] [Abstract][Full Text] [Related]
19. [Concurrent chemoradiotherapy with nedaplatin and 5-fluorouracil (5-fu) for locally advanced squamous cell carcinoma of the esophagus].
Kubo N; Morimoto J; Tanaka H; Ohira M; Noda E; Amano R; Inoue T; Yamada N; Yashiro M; Maeda K; Yamashita Y; Muguruma K; Sawada T; Hirakawa K
Gan To Kagaku Ryoho; 2009 Nov; 36(12):1997-9. PubMed ID: 20037303
[TBL] [Abstract][Full Text] [Related]
20. Treatment strategy for superficial pharyngeal squamous cell carcinoma synchronously combined with esophageal cancer.
Kaneko K; Yano T; Minashi K; Kojima T; Ito M; Satake H; Yajima Y; Yoda Y; Ikematsu H; Oono Y; Hayashi R; Onozawa M; Ohtsu A
Oncology; 2013; 84(1):57-64. PubMed ID: 23128894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
